BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Biopharma exempt from US reciprocal tariffs, but not untouched
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald Trump...

More in BioWorld

BioWorld MedTech

Impact of Trump tariffs on med tech proving difficult to anticipate
The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by company....

More in BioWorld MedTech

BioWorld Science

ADPD 2025: Emerging strategies fueling Alzheimer’s disease research
During the first oral sessions on Translational Drug Discovery at the 19th Alzheimer’s & Parkinson’s Diseases (ADPD) Conference, Beka Solomon from Tel Aviv University...

More in BioWorld Science

BioWorld Asia

Merck opts in for global license of Abbisko’s pimicotinib for $85M
Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld,...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.